- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04227977
Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF) (VOID-HF)
Study Overview
Detailed Description
The Cardiorenal Syndrome during Acute decompensated heart failure (ADHF) with persistent congestion despite high dose IV diuretic therapy is associated with remarkable morbidity, which can include the need for renal dialysis or ultrafiltration, an increased length of stay, and high mortality rates. The primary renal adjuvant therapies for presistent congestion despite high dose IV diuretic therapy are ultrafiltration and dialysis. Unfortunately, clinical decongestion is uncommon in this population despite aggressive therapies. Negative pressure diuresis in the renal pelvis has the potential to treat hypervolemia associated with ADHF by increasing renal filtration and increased urine output.
Primary endpoint: The characterization of the type, frequency, severity, and device-relatedness of adverse events (AEs) associated with the placement, use, and removal of the JuxtaFlow System and a 28-day post-treatment actuarial follow up.
Secondary endpoints: a) Increase in urine output from baseline to discontinuation of treatment with the JuxtaFlow System. b) Reduction of congestion (as measured by change in BNP) during the course of the treatment with the JuxtaFlow System. c) The relative change in creatinine clearance from baseline to treatment period after 24 hours of treatment or until discontinuation of the investigational treatment using each study subject as their own control. The change in creatinine clearance from the baseline period to the 24 hour post End of Treatment (EOT) period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bryan Tucker, PhD
- Phone Number: (470)-268-7673
- Email: info@3ivelabs.com
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Univ. of Texas Health
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Norfolk General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients ≥22 years of age
- Patients admitted with primary diagnosis of ADHF
Persistent volume overload with venous congestion despite at least 24 hours of IV diuretic therapy, including either a single bolus ≥ 100 mg or continuous drip ≥ 10 mg/hour of furosemide equivalent, where:
- Volume overload defined by the presence of pulmonary edema, 2+ peripheral edema, or orthopnea
- Venous congestion defined by at least one of the following:
i. Jugular venous pressure > 10 cm on physical exam ii. Central venous pressure > 10 mmHg iii. Pulmonary capillary wedge pressure > 22 mmHg c) Evidence of low natriuretic response to high dose diuretic therapy defined by spot urine sodium < 70 mmol
- Ability to have the JuxtaFlow® System catheters placed at bedside
- Anticipated to have an inpatient hospital admission that is ≥ 72 hours
- Patients that are willing and able to provide informed consent for this research trial, or if the patient is not able to provide consent due to their clinical condition, a legal guardian, spouse, or next of kin to the patient with medical power of attorney that is willing to provide consent for the patient's participation in this research trial
- Patients who agree to comply with the study procedures and specified evaluations
Exclusion Criteria:
- Females who are pregnant or nursing mothers
- Creatinine > 3.0 mg/dL at admission to the hospital
- Systolic blood pressure < 100 mmHg at the time of enrollment
- Clinical instability likely to require the addition of intravenous vasoactive drugs, vasodilators and/or inotropic agents.
- Alternative explanation for the renal impairment causing the persistent volume overload, such as obstructive nephropathy, contrast induced nephropathy, or acute tubular necrosis
- Any patient with an eGFR < 15 ml/min or prior diagnosis of CKD 5
- Any patient presenting with hematuria as defined by urine dipstick reading of > 1+ blood
- Any patient presenting with proteinuria as defined by urine dipstick reading of > 3+ protein.
- Any patient that would not potentially benefit from this therapy in the opinion of the investigator
- Any patient with a current upper or lower urinary tract infection (tested during pre-screening)
- Any patient with a malignancy of the upper urinary tract
- Any patient who are currently experiencing unexplained/unexpected proteinuria as determined by the investigator
- Any patient with a current unrepaired ureteral avulsion as determined by the investigator
- Any patient that would require an MRI between enrollment and completion of the post-treatment baseline period
- Any secondary condition as determined by the investigator that would place the subject at an increased risk, or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals
- Any use of an iodinated radiocontrast material in the past 72 hours prior to study enrollment or anticipated use of intravenous contrast during the current hospitalization.
Pre-enrollment ultrasound revealing any of the following:
- Congenital abnormality in either kidney
- Only one kidney
- Presence of debris, stones or an obstruction in the renal pelvis, ureter or urinary tract
- Current or planned treatment with an investigational drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
JuxtaFlow
|
The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device related adverse events
Time Frame: 28 days
|
The characterization of the type, frequency, severity, and device-relatedness of adverse events (AEs) associated with the placement, use, and removal of the JuxtaFlow System and a 28-day post-treatment follow up.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine output
Time Frame: 24 hours
|
The change in urine output from baseline to discontinuation
|
24 hours
|
Congestion
Time Frame: 24 hours
|
The change in congestion (as measured by change in BNP) during the course of treatment
|
24 hours
|
Creatinine Clearance
Time Frame: 24 hours
|
The change in creatinine clearance from baseline to discontinuation
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wilson Tang, MD, The Cleveland Clinic
- Principal Investigator: Alex Parker, MD, Univ. of Florida, Gainesville
- Principal Investigator: Shweta Bansal, MD, Univ. of Texas Health, San Antonio
- Principal Investigator: Wayne Old, MD, Sentara Norfolk General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VOID-HF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiorenal Syndrome
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiorenal Syndrome (CRS)United States
-
Instituto Nacional de Cardiologia Ignacio ChavezEchoNous Inc.RecruitingCardiorenal Syndrome Type 1Mexico
-
Chulalongkorn UniversityNot yet recruitingEmpagliflozin in Cardiorenal Syndrome Type 1Thailand
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Enrolling by invitationHeart Failure | Cardiorenal Disease | Renal DisfunctionUnited States
-
Hospital Civil de GuadalajaraCompleted
-
Horng ChenFlowMedica, Inc.TerminatedCardiorenal SyndromeUnited States
-
Maimonides Medical CenterWithdrawn
-
Ankara UniversityCompletedCardiorenal SyndromeTurkey
-
Virginia Commonwealth UniversityTerminatedCongestive Heart Failure | Cardiorenal SyndromeUnited States
-
Göteborg UniversitySahlgrenska University Hospital, SwedenCompletedCardiorenal SyndromeSweden
Clinical Trials on JuxtaFlow System
-
3ive LabsSCIRENTCompletedRenal Insufficiency | Acute Kidney InjurySerbia, Poland
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting